Clinical Trial Update: Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of budesonide/formoterol delivered via a device-metered dry powder inhaler in asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Asthma | Phase 1 | Status: COMPLETED